The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

Abrams, Paul; Cardozo, Linda; Fall, Magnus; Griffiths, Derek; Rosier, Peter; Ulmsten, Ulf; Kerrebroeck, Philip Van; Victor, Arne; Wein, Alan J.

doi:10.1016/s0090-4295(02)02243-4

Cited by 3,748 publications

(3,408 citation statements)

References 13 publications

Supporting

Mentioning

3,087

Contrasting

Unclassified

188

Order By: Relevance

“…However, a simplistic causal relationship linking prostatic overgrowth, progressive urethral obstruction, urinary retention and LUTS, has been challenged, based on the incomplete overlap of prostatic enlargement with symptoms. 2 In fact, investigations into the relation of LUTS, prostate volume and urodynamic parameters failed to identify a causative relationship between parameters of BPH severity and symptoms, suggesting that other factors may intervene in determining LUTS. 3 Although age remains the best-recognized risk factor for LUTS, LUTS may reflect other systemic derangements.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation

Gacci

Vignozzi

Sebastianelli

et al. 2012

Prostate Cancer Prostatic Dis

141

137

View full text Add to dashboard Cite

BACKGROUND: Epidemiological data indicate that lower urinary tract symptoms (LUTS)/BPH can be associated with metabolic syndrome (MetS). Chronic inflammation has been proposed as a candidate mechanism at the crossroad between these two clinical entities. Aim of study is to examine the correlation among pre-operatory LUTS/BPH severity, MetS features and inflammatory infiltrates in prostatectomy specimens. METHODS: A total of 271 consecutive men treated with simple prostatectomy were retrospectively selected for this study in two tertiary referral centers for LUTS/BPH. Prostate diameters and volume were measured by transrectal ultrasound, LUTS scored by International Prostate Symptom Score (IPSS) and obstruction by uroflowmetry. The International Diabetes Federation and American Heart Association and the National Heart, Lung and Blood Institute was used to define MetS. The inflammatory infiltrate was investigated combining anatomic location, grade and extent of flogosis into the overall inflammatory score (IS); the glandular disruption (GD) was used as a further marker. RESULTS: Eighty-six (31.7%) men were affected by MetS. Prostatic volume and anterior-posterior (AP) diameter were positively associated to the number of MetS components. Among MetS determinants, only dyslipidaemia (increased serum triglycerides and reduced serum high-density lipoprotein) was associated with an increased risk of having a prostatic volume 460 cm 3 (hazard ratio (HR) ¼ 3.268, Po0.001). A significant positive correlation between the presence of MetS and the IS was observed. MetS patients presented lower uroflowmetric parameters as compared with those without MetS (Maximum flow rate (Q max ): 8.6 vs 10.1, P ¼ 0.008 and average flow rate (Q ave ): 4.6 vs 5.3, P ¼ 0.033, respectively), and higher obstructive urinary symptoms score (P ¼ 0.064). A positive correlation among both IS-GD and IPSS Score was also observed (adjusted r ¼ 0.172, P ¼ 0.008 and adjusted r ¼ 0.128, P ¼ 0.050). CONCLUSIONS: MetS is associated with prostate volume, prostatic AP diameter and intraprostatic IS. The significantly positive association between MetS and prostatic AP diameter could support the observation that MetS patients presented lower uroflowmetric parameters. In conclusion, MetS can be regarded as a new determinant of prostate inflammation and BPH progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation

Gacci

Vignozzi

Sebastianelli

et al. 2012

Prostate Cancer Prostatic Dis

141

137

View full text Add to dashboard Cite

show abstract

“…When 2 mg of melatonin was administered to patients with nocturia before sleeping, the morning plasma melatonin level was very high [8] compared with that Nocturia is defined as the need to wake once or more times during the night to void [13]. Sleep disturbance is a in persons without nocturia [14].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Melatonin Receptor Agonist Ramelteon and the Non-Benzodiazepine Hypnotic Zolpidem for Nocturia

Mukouyama¹,

Sugaya²,

Nishijima³

et al. 2013

OJU

View full text Add to dashboard Cite

To examine the efficacy of the melatonin receptor agonist ramelteon for nocturia, it was compared with zolpidem, a conventional non-benzodiazepine hypnotic. A total of 50 patients with nocturia (2 urinations/night) were enrolled. Subjects assigned odd numbers or even numbers were respectively prescribed 8 mg of ramelteon (n = 27; mean age: 75 years) or 5 mg of zolpidem (n = 23; mean age: 73 years) once a day before sleeping for 4 weeks. The daytime and nighttime frequencies of urination, as well as the results of global self-assessment by the patients, were compared between the two groups before and after 4 weeks of treatment. Both ramelteon and zolpidem caused a significant decrease of nocturia to about once per night after 4 weeks. The global self-assessment rating at 4 weeks was "good" or "fair" for more patients in the zolpidem group than in the ramelteon group, while the rating was "excellent" or "no change" for more patients in the ramelteon group. There were no serious adverse events in either group. Ramelteon was safe and effective for nocturia, achieving similar results to zolpidem. However, responders and non-responders to ramelteon were more clearly distinguished. Ramelteon might be effective for patients with sleep disturbance and nocturia because of low melatonin levels. Therefore, as diagnostic therapy for identification of nocturia caused by sleep disturbance and melatonin deficiency, ramelteon should be administered to patients who do not respond to alpha-1 antagonists and/or anticholinergic agents.

show abstract

“…Günlük pratiğimizde sıkça kullandığımız sistometri sözcüğünün yerine dolum sistometrisi teriminin kullanılması terminolojinin standardize edilmesi amacıyla ICS tarafından 2002 yılında önerilmiştir (4) . Alt üriner sistemin dolum ve depolama fonksiyonunun değerlendirildiği bu kısımda, basınç ölçmeye yarayan kateter-bazlı bir manometre sistemi kullanılarak mesanenin basınç-hacim eğrisi elde edilmektedir (1) .…”

Section: A) Dolum Sistometrisiunclassified

Urodynamic equipment

Yağmur¹

2016

tcdd

View full text Add to dashboard Cite

show abstract

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

Cited by 3,748 publications

References 13 publications

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation

Comparison of the Melatonin Receptor Agonist Ramelteon and the Non-Benzodiazepine Hypnotic Zolpidem for Nocturia

Urodynamic equipment

Contact Info

Product

Resources

About